These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 33513668)

  • 21. Economic costs of diabetes in the U.S. In 2007.
    American Diabetes Association
    Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Cost of Lost Productivity Due to Premature Chagas Disease-Related Mortality: Lessons from Colombia (2010-2017).
    Olivera MJ; Palencia-Sánchez F; Riaño-Casallas M
    Trop Med Infect Dis; 2021 Jan; 6(1):. PubMed ID: 33513668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden.
    Hanly PA; Sharp L
    BMC Cancer; 2014 Mar; 14():224. PubMed ID: 24670067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Productivity Costs of Premature Mortality Due to Cancer in Australia: Evidence from a Microsimulation Model.
    Carter HE; Schofield DJ; Shrestha R
    PLoS One; 2016; 11(12):e0167521. PubMed ID: 27942032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The long-term productivity impacts of all cause premature mortality in Australia.
    Carter HE; Schofield D; Shrestha R
    Aust N Z J Public Health; 2017 Apr; 41(2):137-143. PubMed ID: 27868363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Lost Productivity Cost of Premature Mortality Owing to Cancers in Iran: Evidence From the GLOBOCAN 2012 to 2018 Estimates.
    Nahvijou A; Daroudi R; Javan-Noughabi J; Dehdarirad H; Faramarzi A
    Value Health Reg Issues; 2022 Sep; 31():1-9. PubMed ID: 35313156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Years of potential life lost and productivity costs due to premature mortality from six priority diseases in Tanzania, 2006-2015.
    Rumisha SF; George J; Bwana VM; Mboera LEG
    PLoS One; 2020; 15(6):e0234300. PubMed ID: 32516340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic costs of Chagas disease in Colombia in 2017: A social perspective.
    Olivera MJ; Buitrago G
    Int J Infect Dis; 2020 Feb; 91():196-201. PubMed ID: 31770619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost of lost productivity due to premature lung cancer-related mortality: results from Spain over a 10-year period.
    Darbà J; Marsà A
    BMC Cancer; 2019 Oct; 19(1):992. PubMed ID: 31646991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Diagnostic Algorithm for Chagas Disease: Impact on Access to Diagnosis and Out-of-Pocket Expenditures in Colombia.
    Olivera MJ; Chaverra KA
    Iran J Public Health; 2019 Jul; 48(7):1379-1381. PubMed ID: 31497563
    [No Abstract]   [Full Text] [Related]  

  • 31. Prevalence of Chagas disease in Colombia: A systematic review and meta-analysis.
    Olivera MJ; Fory JA; Porras JF; Buitrago G
    PLoS One; 2019; 14(1):e0210156. PubMed ID: 30615644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review.
    Pike J; Grosse SD
    Appl Health Econ Health Policy; 2018 Dec; 16(6):765-778. PubMed ID: 30094591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Barriers to Diagnosis Access for Chagas Disease in Colombia.
    Olivera MJ; Porras Villamil JF; Toquica Gahona CC; Rodríguez Hernández JM
    J Parasitol Res; 2018; 2018():4940796. PubMed ID: 29568648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic drug monitoring of benznidazole and nifurtimox: a systematic review and quality assessment of published clinical practice guidelines.
    Olivera MJ; Fory JA; Olivera AJ
    Rev Soc Bras Med Trop; 2017; 50(6):748-755. PubMed ID: 29340450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease.
    Olivera MJ; Cucunubá ZM; Valencia-Hernández CA; Herazo R; Agreda-Rudenko D; Flórez C; Duque S; Nicholls RS
    PLoS One; 2017; 12(9):e0185033. PubMed ID: 28949997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased mortality attributed to Chagas disease: a systematic review and meta-analysis.
    Cucunubá ZM; Okuwoga O; Basáñez MG; Nouvellet P
    Parasit Vectors; 2016 Jan; 9():42. PubMed ID: 26813568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults.
    Olivera MJ; Cucunubá ZM; Álvarez CA; Nicholls RS
    Am J Trop Med Hyg; 2015 Dec; 93(6):1224-1230. PubMed ID: 26392162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality assessment of clinical practice guidelines for Chagas disease.
    Olivera MJ; Fory JA; Olivera AJ
    Rev Soc Bras Med Trop; 2015; 48(3):343-6. PubMed ID: 26108016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chagas disease in Latin America: an epidemiological update based on 2010 estimates.
    Wkly Epidemiol Rec; 2015 Feb; 90(6):33-43. PubMed ID: 25671846
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.